The platelet-rich plasma lysate use in the treatment of persistent epithelial defects after keratoplasty

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

AIM: to evaluate the effectiveness of the platelet-rich plasma lysate (PRP lysate) use in the treatment of persistent epithelial defects (PED) after keratoplasty.

MATERIALS AND METHODS: In the study, 60 patients with PED after keratoplasty were included. The 1st group (24 cases) included patients after keratoplasty with “low risk” of rejection, and the 2nd group – 36 cases after keratoplasty with “high risk” of rejection. Each group was divided into two subgroups – control subgroups 1a (cases 10) and 2a (cases 16), where patients received only standard postoperative therapy, and the main subgroups 1b (cases 14) and 2b (cases 20), in which PRP lysate was prescribed against the background of standard therapy, starting from the Day 15 post-op. As the criterion for effective treatment, complete persistent epithelialization after keratoplasty was considered.

RESULTS: The effectiveness of the use of PRP lysate in the subgroup 1b was 85.7%, while complete epithelialization in the control subgroup 1a was recorded in 70%; in the subgroup 2b, complete epithelialization was observed in 55%, in the control subgroup 2a – in 43.75%.

CONCLUSION: The use of PRP lysate in the treatment of PED after corneal transplantation as an adjuvant therapy is effective and safe in both high and low risk keratoplasty. In the examined category of patients, treatment with blood derivatives increases the frequency and rate of complete epithelialization.

About the authors

Nare P. Shakhbazyan

Research Institute of Eye Diseases

Author for correspondence.
Email: nare_shakhbazyan@mail.ru
ORCID iD: 0000-0002-1857-6425

postgraduate student

Russian Federation, 11A, Roccolimo str., Moscow, 119021

Sergey V. Trufanov

Pavlov First St. Petersburg State Medical University

Email: trufanov05@mail.ru
ORCID iD: 0000-0003-4360-793X

MD, Dr. Sci. (Med.)

Russian Federation, 6–8 L’va Tolstogo str., Saint Petersburg, 197022

Anastasia M. Subbot

Research Institute of Eye Diseases

Email: kletkagb@gmail.com
ORCID iD: 0000-0002-8258-6011

PhD, Cand. Sci. (Med.)

Russian Federation, 11A, Roccolimo str., Moscow, 119021

References

  1. Lynch MD, Bashir S. Applications of platelet-rich plasma in dermatology: A critical appraisal of the literature. Journal of Dermatological Treatment. 2016;27(3):285–289. doi: 10.3109/09546634.2015.1094178
  2. Andia E, Rubio-Azpeitia J, Martin JI, Abate M. Current concepts and translational uses of platelet rich plasma biotechno-logy. Biotechnology, Deniz Ekinci, IntechOpen. 2015. doi: 10.5772/59954
  3. Sommeling CE, Heyneman A, Hoeksema H, et al. The use of platelet-rich plasma in plastic surgery: a systematic review. J Plast Reconstr Aesthet Surg. 2013;66(3):301–311. doi: 10.1016/j.bjps.2012.11.009
  4. Mazzucco L, Balbo V, Cattana E, et al. Not every PRP-gel is born equal. Evaluation of growth factor availability for tissues through four PRP-gel preparations: Fibrinet, Regen PRP-kit, Plateltex and one manual procedure. Vox Sang. 2009;97(2):110–118. doi: 10.1111/j.1423-0410.2009.01188. x
  5. Le G, Kaux JF, Seidel L, et al. Étude comparative de cinq techniques de préparation plaquettaire (platelet-rich plasma). Pathol Biol. (Paris). 2011;59(3):157–160. (In French.) doi: 10.1016/j.patbio.2009.04.007
  6. Castillo TN, Pouliot MA, Kim HJ, Dragoo JL. Comparison of growth factor and platelet concentration from commercial platelet-rich plasma separation systems. Am J Sports Med. 2010;39(2): 266–271. doi: 10.1177/0363546510387517
  7. Wasterlain AS, Braun HJ, Dragoo JL. Contents and formulations of platelet rich plasma. Platelet Rich Plasma in Musculoskeletal Practice. London; 2016. P. 1–29.
  8. Bieback K. Platelet lysate as replacement for fetal bovine serum in mesenchymal stromal cell cultures. Transfus Med Hemother. 2013;40(5):326–335. doi: 10.1159/000354061
  9. Anitua E, Sanchez M, Merayo-Lloves J, et al. Plasma rich in growth factors (PRGF-Endoret) stimulates proliferation and migration of primary keratocytes and conjunctival fibroblasts and inhibits and reverts TGF induced myodifferentiation. Investigative ophthalmology visual science. 2011;52(9):6066–6073. doi: 10.1167/iovs.11-7302
  10. Abu-Ameerh MA, Jafar HD, Hasan MH, et al. Platelet lysate promotes re-epithelialization of persistent epithelial defects a pilot study. Int Ophthalmology. 2019;39(7):1483–1490. doi: 10.1007/s10792-018-0968-1
  11. Santos S, Sigurjonsson ÓE, Custódio CA, Mano J. Blood Plasma Derivatives for Tissue Engineering and Regenerative Medicine Therapies. Tissue Eng Part B Rev. 2018;24(6):454–462. doi: 10.1089/ten.TEB.2018.0008
  12. Amable PR, Carias RB, Teixeira MV, et al. Platelet-rich plasma preparation for regenerative medicine: optimization and quantification of cytokines and growth factors. Stem Cell Res Ther. 2013;4(3):67. doi: 10.1186/scrt218
  13. Drago L, Bortolin M, Vassena C, et al. Antimicrobial activity of pure platelet-rich plasma against microorganisms isolated from oral cavity. BMC Microbiol. 2013;13:47. doi: 10.1186/1471-2180-13-47
  14. Del Fabbro M, Ceresoli V, Lolato A, Taschieri S. Effect of platelet concentrate on quality of life after periradicular surgery: a randomized clinical study. J Endod. 2012;38(6):733–739. doi: 10.1016/j.joen.2012.02.022
  15. van Osch GJ, Bernsen MR, van Buul GM, et al. Platelet-rich plasma releasate inhibits inflammatory processes in osteoarthritic chondrocytes. Am J Sports Med. 2011;39(11):2362–2370. doi: 10.1177/036354651141927
  16. Mazzocca AD, McCarthy BR, Intravia J, et al. An in vitro evaluation of the anti-inflammatory effects of platelet-rich plasma, ketorolac, and methylprednisolone. Arthroscopy. 2013;29(4):675–683. doi: 10.1016/j.arthro.2012.12.005
  17. Peerbooms JC, Sluimer J, Bruijn DJ, Gosens T. Positive effect of an autologous platelet concentrate in lateral epicondylitis in a double-blind randomized controlled trial: Platelet-rich plasma versus corticosteroid injection with a 1-year follow-up. Am J Sports Med. 2010;38(2):255–262. doi: 10.1177/0363546509355445
  18. Deikalo VP, Mastykov AN, Boloboshko KB. Obogashhennaja trombocitami plazma v lechenii zabolevanij i povrezhdenij oporno-dvigatel’nogo apparata. Vestnik VGMU. 2011;10(4):6–12. (In Russ.)
  19. Marx RE. Platelet-rich plasma: evidence to support its use. J Oral Maxillofac Surg. 2004;62(4):489–496. doi: 10.1016/j.joms.2003.12.003
  20. Huang CJ, Sun YC, Christopher K, et al. Comparison of corneal epitheliotrophic capacities among human platelet lysates and other blood derivatives. PloS one. 2018;12(2): e0171008. doi: 10.1371/journal.pone.0171008
  21. McCulley JP, Horowitz B, Husseini ZM, Horowitz M. Topical fibronectin therapy of persistent corneal epithelial defects. Fibronectin Study Group. Trans Am Ophthalmol Soc. 1993;91:367–386.
  22. Fu Y, Liu J, Tseng SC. Ocular surface deficits contributing to persistent epithelial defect after penetrating keratoplasty. Cornea. 2012;31(7):723–729. doi: 10.1097/ICO.0b013e31821142ee
  23. Loshkareva AO. Terapija hronicheskih narushenij jepitelizacii rogovicy gerpesvirusnoj jetiologii s ispol’zovaniem autologichnoj bogatoj trombocitami plazmy [dissertation]. Moscow; 2018. (In Russ.) Available from: https://www.dissercat.com/content/terapiya-khronicheskikh-narushenii-epitelizatsii-rogovitsy-gerpesvirusnoi-etiologii-s-ispolz
  24. Borovkova NV, Filatova IA, Chentsova EV, et al. Efficacy of platelet-rich plasma lysate in patients with corneal erosion or post-traumatic scarring of the tissues of the eyelids. Russian Ophthalmological Journal. 2020;13(3):8–14. (In Russ.) doi: 10.21516/2072-0076-2020-13-3-8-14.
  25. Rumelt S, Bersudsky V, Blum-Hareuveni T, Rehany U. Preexisting and postoperative glaucoma in repeated corneal transplantation. Cornea. 2002;21(8):759–765. doi: 10.1097/00003226-200211000-00005
  26. Rumelt S, Bersudsky V, Blum-Hareuveni T, et al. Preexisting and postoperative glaucoma in repeated corneal transplantation. Cornea. 2002;21(8):759–765. doi: 10.1097/00003226-200211000-00005
  27. Puchkovskaja NA. Lechebnaja keratoplastika i vozmozhnosti stimuljacii regenerativnoj sposobnosti rogovoj obolochki. Oftal’mologichcheskij zhurnal. 1983;2:69–71. (In Russ.)
  28. Katzman LR, Jeng BH. Management strategies for persistent epithelial defects of the cornea. Saudi J Ophthalmol. 2014;28(3): 168–172. doi: 10.1016/j.sjopt.2014.06.011
  29. Hos D, Matthaei M, Bock F, et al. Immune reactions after modern lamellar (DALK, DSAEK, DMEK) versus conventional penetrating corneal transplantation. Prog Retin Eye Res. 2019;73:100768. doi: 10.1016/j.preteyeres.2019.07.001
  30. Trufanov SV, Subbot AM, Malozhen SA, et al. Risk factors, clinical presentations, prevention, and treatment of corneal graft rejection. Vestnik oftal’mologii. 2016;132(6):108–116. (In Russ.) doi: 10.17116/oftalma20161326108-116

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Biomicroscopy of the anterior segment with corneal fluorescein staining under focal illumination in blue cobalt light on Day 15 after keratoplasty: a – Descemet’s stripping automated endothelial keratoplasty; b – penetrating keratoplasty; c – Descemet’s membrane endothelial keratoplasty; d – automated anterior lamellar keratoplasty

Download (155KB)
Indexing metadata
3. Fig. 2. Before treatment start, Day 15 after surgery

Download (115KB)
Indexing metadata
4. Fig. 3. After treatment with platelet-rich plasma lysate, Day 35 after surgery

Download (91KB)
Indexing metadata

Copyright (c) 2021 Shakhbazyan N.P., Trufanov S.V., Subbot A.M.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies